Hypoionic shock treatment enables aminoglycosides antibiotics to eradicate bacterial persisters

Liu Jiafeng1, Xinmiao Fu1,2 & Zengyi Chang1,2

Bacterial persisters, usually being considered as dormant cells that are tolerant to antibiotics, are an important source for recurrent infection and emergence of antibiotic resistant pathogens. Clinical eradication of pathogenic persisters is highly desired but greatly difficult mainly due to the substantial reduction in antibiotics uptake as well as the non-active state of the drug targets. Here we report that bacterial persisters (normal growing cells as well) can be effectively eradicated by aminoglycoside antibiotics upon hypoionic shock (e.g., pure water treatment) even for less than one minute. Such hypoionic shock potentiation effect on aminoglycosides is proton motive force-independent, and is apparently achieved by promoting the entrance of aminoglycosides, speculatively through the mechanosensitive ion channels. Our revelations may provide a simple and powerful strategy to eradicate pathogen persisters.

Bacterial pathogens insusceptible to antibiotics, either due to “resistance” or “tolerance”, are a growing threat to public health worldwide1-4. While resistance is generally caused by acquisition of resistance genes or mutation of the target genes5,6, tolerance is usually due to the bacteria cells entering a non-growing dormant state, commonly defined as persisters, rather than any genetic alteration7-9. As a result, the antibiotics targets are largely in a non-active state and meanwhile the uptake of certain antibiotics (such as aminoglycosides) hardly occurs10,11, both of which make antibiotics inefficient for eradicating pathogen persisters. Additionally, such bacterial persisters may provide a reservoir of pathogens that facilitate the subsequent evolution of antibiotic resistance12-14. Because of these, eradication of bacterial persisters, though being highly desired, is greatly challenging in technical terms.

Aminoglycosides, as represented by streptomycin, tobramycin, kanamycin, gentamicin and amikacin, are commonly used antibiotics against many threatening infectious diseases (e.g., tuberculosis) and are known to act by binding and inhibiting bacterial ribosome15,16. A metabolism recovery-based approach was recently explored in killing bacterial persisters by enhancing proton-motive force-dependent uptake of aminoglycosides11. Here, we attempted to develop a method to efficiently eradicate bacterial persisters also by aminoglycosides, but independent of metabolism recovery.

Results
Hypoionic shock potentiate aminoglycoside antibiotics to eradicate E. coli persisters. During our exploration, we tested whether such physicochemical stress conditions as osmotic shock, among others, would help to promote the effect of aminoglycosides for killing persisters. In this regard, the stationary phase E. coli cells, which are highly insusceptible to such antibiotics as aminoglycosides (Fig. 1a), were also used as model persisters as before11,17,18. We strikingly found that the bacterial persisters were almost completely eradicated after being treated for one hour with tobramycin-containing solution of...
2 M glycerol, but not of 1 M NaCl, although both of which theoretically have an identical osmolarity (i.e., osmotic concentration) (Fig. 1a). This apparently indicates that the bactericidal effect of aminoglycosides observed with the 2 M glycerol treatment could not be simply due to a hyper-osmotic shock effect. Consistent with this analysis, we observed similar bactericidal effects of tobramycin dissolved in solutions of a wide spectrum of glycerol concentrations, from hyper-osmotic to iso-osmotic to hypo-osmotic (Fig. 1b). It was reported that glycerol, at a concentration of 20 mM and dissolved in M9 salts, is able to potentiate aminoglycosides against bacterial persisters11. Here, glycerol is unlikely to act in a similar way, because of its far higher concentration and also the lack of other essential salts for growth. In addition, we also demonstrated that tobramycin-containing solutions of non-metabolizable osmolyte DMSO19 or xylitol20 exhibited similar eradication effect (Supplementary Fig. 1). Remarkably, for the effect of NaCl, we noticed that the bactericidal efficiency of tobramycin increases upon a decrease of NaCl concentration, achieving an eradication effect when NaCl became completely absent, i.e., only in the presence of water (Figures 1a, 1b).

These observations indicate that the effect of our treatment to potentiate tobramycin to eradicate persisters is apparently attributed to the lowering of ionic strength of the treating solutions. In this regard, we observed that adding NaCl at a concentration as low as 0.2 M could abolish the potentiation effect of the glycerol solution on tobramycin (Fig. 1c). In general, we found that treating in non-electrolyte (as glycerol) solutions exhibits similar potentiation effect for tobramycin to eradicate persisters, while treating in strong electrolyte (as NaCl) solutions hardly exhibits any such potentiation effect (Supplementary Fig. 1). Our dosage effect analyses reveal that upon such hypoionic shock treatment, about 99.9% of the stationary phase cells were killed in the presence of tobramycin at a concentration of 25 μg/ml, and achieving an effective eradication at 500 μg/ml (Supplementary Fig. 2). Furthermore, such hypoionic shock are apparently effective for aminoglycoside antibiotics in general, as similarly observed for streptomycin and kanamycin, but not for the other two major types of bactericidal antibiotics, either β-lactams (as represented by ampicillin) that inhibit cell wall synthesis, or quinolones (as represented by ofloxacin) that inhibit DNA synthesis (Supplementary Fig. 3). Taken together, these observations implicate that hypoionic (i.e. low ionic strength) shock treatment specifically promote the aminoglycoside type of antibiotics to eradicate E. coli persisters.
The potentiation effect of hypoionic shock on aminoglycoside antibiotics is instant and independent of proton-motive force. We next demonstrated that, to be effective, tobramycin has to be present during the hypoionic shock treatment, while adding it afterwards becomes hardly effective (Supplementary Fig. 4). This suggests that the potentiation effect is generated during but not after the hypoionic shock treatment. Our further analysis indicate that E. coli persisters could be almost completely killed after being treated for as short as 2 minutes (or about 99.9% killed even after only 10 seconds treatment) by tobramycin under our hypoionic shock condition (Fig. 2a). It is noteworthy that similar short-time exposure of tobramycin under hypoionic shock treatment was found to be able to eradicate exponential phase non-persister E. coli cells, which otherwise may take hours of tobramycin exposure to achieve similar eradication effect (Figure 2b, Supplementary Fig. 5). Consistently, a two-minute hypoionic shock treatment was also found to enable tobramycin to efficiently eradicate conditioned E. coli persister cells (Fig. 2b), which were made insusceptible to antibiotics by treating exponential phase cells with bacteriostatic compound rifampicin (being an transcription inhibitor) or placing the cells at a low temperature of 4 °C (both for one hour)⁷. Furthermore, we demonstrated that the potentiation effect of short-time hypoionic shock treatment for aminoglycoside antibiotic to eradicate E. coli persisters was found to be independent of the proton-motive force across the plasma membrane (Supplementary Fig. 6), as the persister-killing effect largely remained even in the presence of carbonyl cyanide m-chlorophenyl hydrazone (CCCP), an uncoupler that was previously reported to eliminate the proton-motive force and to abolish the uptake of aminoglycosides¹¹,¹⁵. Taken together, these observations apparently indicate that the potentiation effect of hypoionic shock on aminoglycoside antibiotics against persister cells is instant and independent of the proton-motive force.

Ribosomes are possibly the target for aminoglycoside antibiotics to eradicate persisters upon hypoionic shock treatment. We next found that, upon such hypoionic shock treatment, the aminoglycoside antibiotics kill persister E. coli cells still by inhibiting the 30S ribosome subunit, being their conventional target¹⁵. In particular, we demonstrated that the persister cells of the E. coli strain MC4100, which is resistant only to streptomycin but not to other aminoglycoside antibiotics (e.g. tobramycin) due to the occurrence of a unique point mutation on the 30S ribosomal subunit protein S12²¹, could no longer be eradicated by streptomycin even with our hypoionic shock treatment (Fig. 3a). This observation suggests that the aminoglycoside antibiotics apparently have entered the cells upon the hypoionic shock. In support of our conclusion, it was reported about half a century ago that the entrance of streptomycin-¹⁴C into exponentially growing E. coli cells was significantly enhanced after being diluted with distilled water²². Further, it was reported before that the uptake of aminoglycosides into bacterial cells is irreversible²³. It follows that the cell death most likely occurs due to and upon the reawakening of the persisters, when the killing effect of the antibiotics is realized.

In support of this conclusion, we observed that the persister cells treated with tobramycin under hypoionic shock condition started to die soon after being incubated in antibiotics-free LB growth medium but not in phosphate buffer saline (PBS), as demonstrated either by time-dependent fluorescence-activated cell sorting analysis or direct fluorescent microscopy imaging (at 30 minutes staining) after the dead cells being stained with the fluorescent dye propidium iodide (Fig. 3b). The misshaping of the cells that were plated in LB agarose growth medium for 2 hours was also clearly observed by regular microscopy (Fig. 3c).
The aminoglycoside antibiotics is hypothesized to enter the persister cells through the mechanosensitive ion channels upon the hypoionic shock treatment. In retrospect, the hypo-osmotic shock (a type of hypoionic shock) was reported to activate bacterial mechanosensitive ion channels, being non-specific and passive ion transporters located on the plasma membrane\textsuperscript{24–26}. It was recently reported that the potency of aminoglycoside streptomycin depends on the expression of a mechanosensitive ion channel in \textit{E. coli} cells\textsuperscript{27}. In this regard, our observation that the potentiation effect could be strongly suppressed by such ions as NaCl (Fig. 1c; Supplementary Fig. 1) suggests one possibility that the aminoglycosides enters the bacteria cells through mechanosensitive ion channels upon our hypoionic shock treatment. It has been reported that such mechanosensitive ion channels open only for a short moment upon hypo-osmotic shock treatment\textsuperscript{28}, which apparently explains our observation that adding the aminoglycosides after the shock becomes hardly effective (Supplementary Fig. 4). It should be pointed out that the diameter of an active mechanosensitive channel could be as large as 30 Å\textsuperscript{24,29}, which would allow such small molecules as aminoglycosides (with a molecule mass of about 500 Dalton) to effectively pass through.

Nevertheless, in a preliminary study, we failed to observe any significant decrease of the hypoionic shock-promoted bactericidal effect of tobramycin against persister cells when each of the seven \textit{E. coli} genes encoding the mechanosensitive channels was individually deleted (Supplementary Fig. 7), most likely due to the functional redundancy of the mechanosensitive channels\textsuperscript{30}. We did not perform this study using mutants having a combined deletion of two or more genes encoding the mechanosensitive channels, because such combined mutation was reported to decrease the viability of the bacteria against hypo-osmotic shock\textsuperscript{26,31}. Evidently, such mutants are inappropriate for testing our hypoionic shock-promoted bactericidal effect of tobramycin.

Furthermore, we found that hypoionic shock treatment also significantly promoted the bactericidal effect of tobramycin against conditioned persister cells of Gram-positive bacterium \textit{S. aureus}, which were prepared by treating the exponential phase cells with bacteriostatic antibiotics rifampicin or placing the cells at a low temperature of 4°C (Supplementary Fig. 8). We found that tobramycin exhibited only mild eradication effect to the \textit{S. aureus} stationary phase cells upon such hypoionic shock treatment (Fig. 4). This inefficiency might reflect the fact that they possess thicker cell wall in comparison with either the
exponential phase cells or the stationary phase cells of Gram-negative bacteria, such that their mechanosensitive ion channels may become less sensitive to hypoionic shock. To the *S. aureus* cells, we found that the presence of indole or propyl-paraben, each being a chemical activator of mechanosensitive ion channels, greatly increased the bactericidal effect of tobramycin under hypoionic shock conditions (Fig. 4), which is consistent with our hypothesis that the aminoglycoside antibiotics may enter the persisting cells through the mechanosensitive ion channels. Nevertheless, our data here do not rule out the possibility that the potentiation effect is generated through a nonspecific increase of the permeability of the cell membrane.

**Discussion**

In summary, here we report a simple and effective method for eradicating bacterial persisters (normal growing cells as well) such that the instant entrance of aminoglycoside antibiotics is promoted by a hypoionic shock treatment. Our findings implicate a possibility that enhancing the activity of pathogens’ mechanosensitive ion channels by physical (e.g. hypoionic shock) and/or chemical (e.g. indole and parabens) manipulations may in general increase the bactericidal efficiency of the aminoglycoside type of antibiotics (as illustrated in Fig. 5). In clinical terms, our strategy may help to fight against the infectious pathogens with increasing tolerance and resistance towards antibiotics, particularly for infections in exposed areas of the body (e.g. the skin and the surface of alimentary canal). One challenging issue for the potential application of our method is how to avoid the suppressing effect of ions naturally present in the infected sites.

**Methods**

**Antibiotics and chemicals.** For treating exponential phase bacterial cells, the concentrations of antibiotics were used as follows: Ampicillin 50 μg/ml, kanamycin 50 μg/ml, tobramycin 25 μg/ml, ofloxacin 5 μg/ml, streptomycin 100 μg/ml, rifampicin 100 μg/ml. For treating stationary phase cells, all concentrations were 20 folds higher in view of the much higher cell density. Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) (20 μM), propidium iodide (PI) (50 μg/ml), indole (1 mM), propyl 4-hydroxybenzoate (paraben) (1 mM) and all the antibiotics were of analytical grade.

**Bacterial strains, media and growth conditions.** Stationary phase Gram-negative *Escherichia coli* bacteria cells of strains BW25113 and MC4100 or Gram-positive *Staphylococcus aureus* bacteria cells

---

**Figure 4.** Aminoglycoside antibiotics enter persister cells likely through mechanosensitive ion channels under hypoionic shock condition. Survival ratio of stationary phase Gram-positive *S. aureus* bacterial cells after being treated with tobramycin-containing (500 μg/ml) distilled water in the presence of 1 mM indole or 1 mM propyl-paraben. Cells treated with indole- or paraben-containing distilled water serves as the control. The data represent mean ± s.d. of three independent experiments. **P < 0.01.

**Figure 5.** Hypothetic illustration for hypoionic shock-promoted entrance of aminoglycoside antibiotics into bacteria cells. Based on our hypothesis, the mechanosensitive ion channels are directly activated by membrane tension upon hypoionic shock treatment, and the ionic aminoglycoside antibiotics instantly enter the persisting bacteria cells down the concentration gradient. Such entrance of aminoglycoside antibiotics is irreversible and lead to bacteria cell death due to and upon cell re-awakening.
of the strain ATCC 25923 were prepared by overnight culturing frozen stock bacteria cells at 37°C, 200 r.p.m. in 20 ml of Luria-Bertani (LB) growth medium. For preparing exponential phase cells, the stationary phase cells were diluted 1:500 in 20 ml LB growth medium and further cultured at 37°C, 200 r.p.m. to an OD600 of ~0.4–0.6.

**Cell treatment.** A volume of 100 μl exponential phase (about 2 × 10^7 cells) or stationary phase (about 5 × 10^8 cells) cultured bacteria were harvested by centrifugation at 10,000 g for 1 minute, resuspended in 100 μl of selected tobramycin-containing solutions, incubated for a specified time, washed and serially diluted in PBS, before spotted on LB plates for survival ratio measurements. The colony forming units (CFU) were counted after the cells were incubated overnight at 37°C.

**Conditioned persister cells.** They are prepared by treating exponential phase bacterial cells with 100 μg/ml rifampicin or being placed at 4°C for 1 hour.

**Dead cell staining.** Stationary phase *E. coli* cells (100 μl) were harvested and treated with 100 μl tobramycin-containing (500 μg/ml) distilled water, before washed and incubated at room temperature (20°C) in PBS or LB, each containing propidium iodide (PI) (50 μg/ml). At a given time point, samples were analyzed on a BD Accuri C6 flow cytometer with the following settings: detector, FL2; flow rate, 14 μl/min.; core size, 10 μm.

**Microscopy.** Samples were plotted on agarose after PI staining. Images were recorded at 30°C with an N-SIM imaging system (Nikon) equipped with a 100X/1.49 NA oil-immersion objective (Nikon) and laser beams (561 nm).

**Statistical methods.** Each survival ratio analysis was performed with samples collected from three independent cultures and data were presented as mean ± standard deviation. The survival ratio was calculated by dividing the CFU number of the experimental (treated) group by that of the control (untreated) group. The two-tailed Student's *t*-test was used to calculate the *p*-values for certain experiments (Fig. 4). For fluorescence-activated cell sorting (FACS) analysis (Fig. 3b), the data represent mean fluorescence intensity of ~50,000 cells (the same pattern was observed in three independent experiments).

**References**

1. Bush, K. et al. Tackling antibiotic resistance. Nat. Rev. Micro. 9, 894–896 (2011).
2. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. Review on Antimicrobial Resistance. (2014) Available at: http://amr-review.org/ (Accessed: 11 December 2014)
3. Antimicrobial resistance Global Report on Surveillance. WHO. (2014) Available at: http://www.who.int/drugresistance/documents/ surveillancerereport/en/ (Accessed: April 2014)
4. Antibiotic resistance threats in the united states. CDC. (2013) Available at: http://www.cdc.gov/drugresistance/threat-report-2013/ (Accessed: 17 July 2014)
5. Alekshun, M. N. & Levy, S. B. Molecular Mechanisms of Antibacterial Multidrug Resistance. *Cell* 128, 1037–1050 (2007).
6. Toprak, E. et al. Evolutionary paths to antibiotic resistance under dynamically sustained drug selection. *Nat Genet* 44, 101–105 (2012).
7. Bigger, I. Treatment of staphylococcal infections with penicillin by intermittent sterilisation. *Lancet* 244, 497–500 (1944).
8. Balaban, N. Q., Merrin, J., Chait, R., Kowalik, L. & Leibler, S. Bacterial persistence as a phenotypic switch. *Science* 305, 1622–1625 (2004).
9. Lewis, K. Persister cells. *Annu. Rev. Microbiol.* 64, 357–72 (2010).
10. Maisonneuve, E. & Gerdes, K. Molecular mechanisms underlying bacterial persisters. *Cell* 157, 539–548 (2014).
11. Allison, K. R., Brynildsen, M. P. & Collins, J. J. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. *Nature* 473, 216–20 (2011).
12. Fridman, O., Goldberg, A., Ronin, I., Shoreh, N. & Balaban, N. Q. Optimization of lag time underlies antibiotic tolerance in evolved bacterial populations. *Nature* 513, 418–421 (2014).
13. Levin, B. R. & Rosen, D. E. Non-inherited antibiotic resistance. *Nat. Rev. Microbiol.* 4, 556–562 (2006).
14. Smith, P. A. & Romesberg, F. E. Combating bacteria and drug resistance by inhibiting mechanisms of persistence and adaptation. *Cell* 157, 539–548 (2014).
15. Davis, B. D. Mechanism of bactericidal action of aminoglycosides. *Microbiol. Rev.* 51, 341–50 (1987).
16. Magnet, S. & Blanchard, J. S. Molecular insights into aminoglycoside action and resistance. *Chem. Rev.* 105, 477–98 (2005).
17. Conlon, B. P. et al. Activated ClpP kills persisters and eradicates a chronic biofilm infection. *Nature* 503, 365–70 (2013).
18. Lebeaux, D. et al. pH-Mediated Potentiation of Aminoglycosides Kills Bacterial Persisters and Eradicates *In Vivo* Biofilms. *J. Infect. Dis.* 210, 1357–1366 (2014).
19. Lim, J. Y., May, J. M. & Cegelski, L. Dimethyl Sulfoxide and Ethanol Elicit Increased Amyloid Biogenesis and Amyloid-Integrated Biofilm Formation in Escherichia coli. *Appl. Environ. Microbiol.* 78, 3369–3378 (2012).
20. Reiner, A. M. Genes for ribitol and D-arabitol catabolism in *Escherichia coli*: their loci in C strains and absence in K-12 and B strains. *J. Bacteriol.* 123, 530–536 (1975).
21. Casadaban, M. J. Transposition and fusion of the lac genes to selected promoters in *Escherichia coli* using bacteriophage lambda and Mu. *J. Mol. Biol.* 104, 541–555 (1976).
22. Plotz, P. H., DUBIN, D. T. & DAVIS, B. D. Influence of Salts on the Uptake of Streptomycin by *Escherichia coli*. *Nature* 191, 1324–1325 (1961).
23. Nichols, W. W. & Young, S. N. Respiration-dependent uptake of dihydrostreptomycin by *Escherichia coli*. Its irreversible nature and lack of evidence for a uniport process. *Biochem. J.* 228, 505–512 (1985).
24. Kung, C., Martinac, B. & Sukharev, S. Mechanosensitive channels in microbes. *Annu. Rev. Microbiol.* 64, 313–29 (2010).
25. Wood, J. M. Bacterial osmoregulation: a paradigm for the study of cellular homeostasis. *Annu. Rev. Microbiol.* 65, 215–38 (2011).
26. Levina, N. *et al.* Protection of Escherichia coli cells against extreme turgor by activation of MscS and MscL mechanosensitive channels: identification of genes required for MscS activity. *EMBO J.* **18**, 1730–1737 (1999).

27. Iscla, I., Wray, R., Wei, S., Posner, B. & Blount, P. Streptomycin potency is dependent on MscL channel expression. *Nat. Commun.* **5**, 4891 (2014).

28. Naismith, J. H. & Booth, I. R. Bacterial mechanosensitive channels--MscS: evolution’s solution to creating sensitivity in function. *Annu. Rev. Biophys.* **41**, 157–77 (2012).

29. Cruickshank, C. C., Minchin, R. F., Le Dain, A. C. & Martinac, B. Estimation of the pore size of the large-conductance mechanosensitive ion channel of Escherichia coli. *Biophys. J.* **73**, 1925–1931 (1997).

30. Sukharev, S. I., Blount, P., Martinac, B., Blattner, F. R. & Kung, C. A large-conductance mechanosensitive channel in E. coli encoded by mscL alone. *Nature* **368**, 265–268 (1994).

31. Bialecka-Fornal, M., Lee, H. J. & Phillips, R. The rate of osmotic downshock determines the survival probability of bacterial mechanosensitive channel mutants. *J. Bacteriol.* **197**, 231–7 (2015).

32. Dijkstra, A. J. & Keck, W. Peptidoglycan as a barrier to transenvelope transport. *J. Bacteriol.* **178**, 5555–5562 (1996).

33. Whatmore, A. M. & Reed, R. H. Determination of turgor pressure in Bacillus subtilis: a possible role for K+ in turgor regulation. *J. Gen. Microbiol.* **136**, 2521–2526 (1990).

34. Haynes, W. J. *et al.* Indole and other aromatic compounds activate the yeast TRPY1 channel. *FEBS Lett.* **582**, 1514–1518 (2008).

35. Nguyen, T., Clare, B., Guo, W. & Martinac, B. The effects of parabens on the mechanosensitive channels of E. coli. *Eur. Biophys. J.* **34**, 389–395 (2005).

**Acknowledgements**

We thank NBRP-E.coli at NIG for providing the Keio Collections, Dr. Chunyan Shan for her professional technical assistance in microscopy at Core Facilities of College of Life Sciences, Peking University, and Mr. Yang Liu, Ms. Jiayu Yu and Mr. Rui Wang in the Chang Lab for advice and discussions. This work was supported by research grants from the National Basic Research Program of China (973 Program) (No. 2012CB917300 to ZYC and XMF) and the National Natural Science Foundation of China (No. 31470766 and No. 31170738 to ZYC; No. 31270804 to XMF).

**Author Contributions**

L.J.F. conceived and conducted the experiments. L.J.F., X.M.F. and Z.Y.C. analyzed the results and prepared the manuscript.

**Additional Information**

Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Jiafeng, L. *et al.* Hypoionic shock treatment enables aminoglycosides antibiotics to eradicate bacterial persisters. *Sci. Rep.* **5**, 14247; doi: 10.1038/srep14247 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/